Absci (NASDAQ:ABSI – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Zacks reports. The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.77 million. Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%.
Absci Price Performance
Shares of NASDAQ:ABSI opened at $2.98 on Thursday. The firm’s 50 day moving average price is $3.87 and its 200-day moving average price is $3.68. Absci has a twelve month low of $2.45 and a twelve month high of $6.72. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $342.27 million, a PE ratio of -3.20 and a beta of 2.09.
Wall Street Analysts Forecast Growth
ABSI has been the topic of a number of recent analyst reports. KeyCorp dropped their price target on shares of Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Absci in a report on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $10.00 price target on shares of Absci in a report on Tuesday, December 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Absci in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $8.57.
Absci Company Profile
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
See Also
- Five stocks we like better than Absci
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Intel Stock Rallies on Leadership Change—Time to Buy or Wait?
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Semiconductor Stocks Flying Under the Radar—But Not for Long
- How to Invest in Blue Chip Stocks
- Despite Downturns, Analysts Say These 4 Financial Stocks Are Buys
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
